February 7, 2014
The Second Wave Arrives
Two more HCV drugs were newly approved in late 2013: the protease inhibitor simeprevir (Olysio) and the nucleotide polymerase inhibitor sofosbuvir (Sovaldi).
By comparison to the two previously approved HCV protease inhibitors, simeprevir appears to be significantly more friendly toward coadministration with HIV medications (particularly HIV protease inhibitors) and has a high efficacy rate in HCV treatment-naive coinfected patients, even allowing many to dramatically shorten the typical course of HCV therapy. However, the drug must still be coadministered with peginterferon, leaving toxicity as a major issue.
Peginterferon is also part of a sofosbuvir-containing regimen at the moment, but only for genotype 1 patients. For patients with genotype 2 or 3, the drug is dosed alongside only ribavirin, and dramatically lower adverse event rates accompany that indication. Sofosbuvir also appears to have virtually no interactions with HIV antiretrovirals.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|This Week in HIV Research: "Can Opener" Molecule Exposes HIV, and How Much Does HIV Age You?|
|More Age-Related Illnesses in Older People With HIV Than Comparable HIV-Negatives|
|CROI 2015: The Future of Pre-Exposure Prophylaxis (Video)|
|New HIV Treatment Guidelines, and the End of an Era|
|This Week in HIV Research: Another Route for Gene Therapy; Drugmaker and University Team Up for HIV Cure|
|HIV-Positive Individuals on Treatment Lose More Years of Life to Smoking Than to HIV|